BioCode® Respiratory Pathogen Panel (RPP)

The BioCode Respiratory Pathogen Panel (RPP) is a qualitative multiplexed nucleic acid-based in vitro diagnostic test

intended for use with BioCode MDx-3000 Instrument. The BioCode RPP is capable of the simultaneous detection and

identification of nucleic acids from multiple viruses and bacteria extracted from nasopharyngeal swab (NPS) samples

obtained from individuals with signs and/or symptoms of respiratory tract infection. The following pathogens and

subtypes are identified using the BioCode RPP:

• Adenovirus

• Coronavirus (229E, OC43, HKU1, and NL63)

• Human Metapneumovirus A/B

• Influenza A, including subtypes H1, H1 2009 Pandemic, and H3

• Influenza B

• Parainfluenza 1

• Parainfluenza 2

• Parainfluenza 3

• Parainfluenza 4

• Respiratory Syncytial Virus A/B

• Rhinovirus/Enterovirus

• Bordetella pertussis

• Chlamydia pneumoniae

• Mycoplasma pneumoniae

The detection and identification of specific viral and bacterial nucleic acids from individuals exhibiting signs and/or

symptoms of a respiratory infection aids in the diagnosis of respiratory infection if used in conjunction with other clinical

and epidemiological information. The results of this test should not be used as the sole basis for diagnosis, treatment, or

other patient management decisions.

Negative results in the setting of a respiratory illness may be due to infection with pathogens that are not detected by this

test, or lower respiratory tract infection that may not be detected by a nasopharyngeal swab specimen. Positive results do

not rule out co-infection with other organisms: the agent(s) detected by the BioCode RPP may not be the definite cause of

disease. Additional laboratory testing (e.g., bacterial and viral culture, immunofluorescence, and radiography) may be

necessary when evaluating a patient with a possible respiratory tract infection.

Due to the genetic similarity between Human Rhinovirus and Enterovirus, the BioCode RPP cannot differentiate them. A

positive BioCode RPP Rhinovirus/Enterovirus result should be followed up using an alternate method (e.g., cell culture or

sequence analysis) if differentiation is required. The BioCode RPP detects Human Rhinovirus/Enterovirus with reduced

sensitivity. If a more accurate HRV/EV result is required, it is recommended that specimens found to be negative for

Human Rhinovirus/Enterovirus after examination using BioCode RPP be confirmed by an alternate method (e.g., FDA

cleared molecular tests).

Performance characteristics for Influenza A were established when Influenza A H1 2009 Pandemic and A H3 were the

predominant Influenza A viruses in circulation. Performance of detecting Influenza A may vary if other Influenza A

strains are circulating, or a novel Influenza A virus emerges. If infection with a novel Influenza A virus is suspected based

on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be

collected with appropriate infection control precautions for novel virulent Influenza viruses and sent to state or local

health departments for testing. Viral culture should not be attempted in these cases unless a BSL 3+ facility is available to

receive and culture specimens.